EXHIBIT 10.17


THIS   SUPPLEMENT  NO.  2  TO  THE  SUBLICENSE   AND  SUPPLY   AGREEMENT   (this
"Supplement"),  effective as of June 26, 2002 (the "Effective  Date") is entered
into  by and  between  TRINITY  ASSETS  COMPANY  LIMITED  ("  TAC"),  a  company
incorporated  in  Thailand,  and  TRINITY  MEDICAL  GROUP USA,  INC.,  a Florida
corporation ("TMGUSA"), with respect to the following facts.

     A.   TRINITY MEDICAL GROUP USA, INC. (" TMGUSA") and TRINITY ASSETS COMPANY
          LIMITED  (" TAC")  entered  into a  Sublicense  and  Supply  Agreement
          ("Sublicense  and Supply  Agreement")  dated August 4, 2000, and first
          amended through the SUPPLEMENT TO THE SUBLICENSE AND SUPPLY  AGREEMENT
          dated  August  5,  2000,  both  parties  hereby  agree to  amend  said
          Sublicense  and Supply  Agreements  under the terms and  conditions of
          this agreement.

NOW, THEREFORE, the parties agree as follows:

                                    ARTICLE 1
                              TERM AND TERMINATION

This  Supplement  shall  terminate  after the first of the  following two events
occurs:

(i) Purchase of the first  1,000,000  units of Product from IRC by TMGUSA or its
successors; or
(ii) December 31, 2007.

                                    ARTICLE 2
                                    AMENDMENT

Article  4.1 of the  Sublicense  and  Supply  Agreement  shall be deleted in its
entirety and restated to read as follows:


Purchase and Sale of Products
-----------------------------

TMGUSA  agrees to sell the  Product  to TAC at the  price  equal to US $50 above
TMGUSA's cost of the Product for each [100 micrograms dose] purchased.

Article 4.4 of the Sublicense and Supply Agreement shall be added as follows:

Product Purchase Commitment
---------------------------

TAC  commits to  purchase a minimum of  1,000,000  units of Product  from TMGUSA
during the three year period  beginning after the date the first unit of Product
is purchased by TMGUSA (from IRC) for commercial sale to TAC in Thailand.

<PAGE>

                                    ARTICLE 3
                                  CONSIDERATION

Consideration
-------------

3.1 Trinity shall provide the following to TAC as consideration for the addition
of  Article  4.4 above and for TAC  absorbing  50% of the  increase  in  Product
purchase  price  allocated  to  IRC  as  per  Amendment  No.  3 to  License  and
Collaboration Agreement by and between TMGUSA and IRC, dated June 26, 2002:

(i) TMGUSA  shall  provide to TAC two (2) million  shares of IRC stock issued by
IRC in  connection  with the  execution  of the  Amendment  No. 3 to License and
Collaboration  Agreement by and between  TMGUSA and IRC, dated June 26, 2002, as
soon as  administratively  practicable  after  receipt of the IRC stock first by
TMGUSA.

(ii)  TMGUSA  shall  provide to TAC one (1)  million  shares  issued by IRC upon
execution of Amendment No. 3 to License and Collaboration  Agreement in exchange
for $1  Million  of  outstanding  debt owed by TMGU to TAC and which  will occur
within  fifteen  business  days of execution  of Amendment  No. 3 to License and
Collaboration Agreement by and between TMGUSA and IRC, dated June 26, 2002.

(iii) TMGUSA shall provide to TAC one (1) million  shares issued by IRC, as soon
as administratively practicable after receipt of the IRC shares first by TMGUSA,
and only upon receipt of purchase order from TAC and when TAC  irrevocably  pays
its  purchase  price to TMGUSA for an  accumulated  amount of  300,000  doses of
REMUNE.

(iv) TMGUSA shall  provide to TAC one (1) million  shares issued by IRC, as soon
as administratively practicable after receipt of the IRC shares first by TMGUSA,
and only upon receipt of purchase order from TAC and when TAC  irrevocably  pays
its  purchase  price to TMGUSA for an  accumulated  amount of  600,000  doses of
REMUNE.

(v) TMGUSA shall provide to TAC one (1) million shares issued by IRC, as soon as
administratively  practicable  after  receipt of the IRC shares first by TMGUSA,
and only upon receipt of purchase order from TAC and when TAC  irrevocably  pays
its purchase  price to TMGUSA for an  accumulated  amount of 1,000,000  doses of
REMUNE.

          IN WITNESS  WHEREOF,  the parties have executed this  Supplement as of
     the date set forth above.

     For and on behalf of
     TRINITY MEDICAL GROUP USA, INC.

     By:

     /s/ James Namnath                  /s/ Vina Churdboonchart
     -----------------                  -----------------------
     James Namnath, CEO                 Vina Churdboonchart, President

     For and on behalf of
     TRINITY ASSETS COMPANY LIMITED

     By:

     /s/ Inthanom Churdboonchart        /s/ Orranart Churdboonchart
     ---------------------------        ---------------------------
     Inthanom Churdboonchart            Orranart Churdboonchart